SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

BPTH RSS Feed
Add BPTH Price Alert      Hide Sticky   Hide Intro
Moderator: SJSTOCKSHARK
Search This Board: 
Last Post: 12/9/2017 8:22:37 PM - Followers: 47 - Board type: Free - Posts Today: 0

Bio-path Holdings Inc.

Company Description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with LDAC) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug and begun phase II. The patient dosing has begun at trials which will occur at up to 10 sites or more, including MD Anderson, Weill Cornell Medical College Presbyterian Hospital,
Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the beginning of phase 2 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. The combination safety trials with LDAC are complete. Phase 2 has begun and is accepting patients. This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may explore FDA accelerated status after testing is complete on 19 additional patients which is expected to occur in the 4th quarter of 2017.

CML combination drug safety study with Sprycel (Dasatinib) for BP1001 has begun at MD Anderson.

Patent protection for their neutral lipid delivery system has been allowed.
 
Bio-Path Holdings will also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected for early 2017.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.


http://www.biopathholdings.com


While antisense drugs fell out of favor following Gilead's failed efforts there is now renewed interest. Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. If Bio-Path holdings proves the validity of their delivery system, I would expect similar partnerships.

This link to the company website describes their novel delivery technology:


http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising an additional funds  the company has 6+ million in cash. These funds should allow the company to start phase II testing of their antisense drug BP1001 on leukemia and begin phase I testing for breast cancer. The company has an "at the market" credit facility in place with Cantor Fitzgerald to raise another $25 million.

 
Bio-Path Holdings do not manufacture their drug but uses contractors. Once the efficacy of BP1001 is established, I would anticipate a manufacturing partnership will occur. The CEO says the company has now ramped up their structure as they are a phase 2 developmental company.
 
BPTH is traded on the NASDAQ.

Here is the link to the peer paper prepared by their experts:


http://www.abstractsonline.com/pp8/#!/4292/presentation/2610

http://www.biopathholdings.com/pdf/PeerExpertOpinion20150107.pdf

Analyst target price: Maxim $2, Rodman & Renshaw $5, HC Wainwright a buy with a $1.50 target, Stonegate Capital Blackstone $4. Thompson Reuters rates BPTH as out perform with a target of $3.25. MSCI raised BPTH from 1 to 3.


Zack's rating now equals hold.

                        
 
 
 
SureTrader
Interactive Brokers Advertisement
BPTH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#3371   Blair, If the issue was truly PN as SJSTOCKSHARK 12/09/17 08:22:37 PM
#3370   Their issue was with PN from what I dmoffat 12/09/17 07:35:02 PM
#3369   Do you think maybe Sing and Garrison might blairsoldman 12/09/17 04:40:13 PM
#3368   Has anyone heard why Amy Sing MD and SJSTOCKSHARK 12/08/17 06:59:06 PM
#3367   I will bet you any amount of money iloveu2 12/08/17 03:53:22 PM
#3366   No, it did not iloveu2 12/08/17 03:50:51 PM
#3365   You try to guess the bottom and that allbetson 12/08/17 01:33:53 PM
#3364   I still have an order to buy at Since2008 12/08/17 01:07:50 PM
#3363   Looks like the bottom may have been hit allbetson 12/08/17 12:50:21 PM
#3362   It is legally irrelevant that the number of wordlender 12/08/17 12:00:12 PM
#3361   iluv, Did your order fill? SJSTOCKSHARK 12/08/17 10:26:38 AM
#3360   Iluv, There is no BK in the near SJSTOCKSHARK 12/07/17 10:26:43 PM
#3359   I had a buy order in for 19 iloveu2 12/07/17 06:48:38 PM
#3358   Blair and SJ, I stand corrected. I Runninonempty 12/07/17 04:47:33 PM
#3357   Experts say no one can predict the bottom allbetson 12/07/17 11:59:12 AM
#3356   If you voted yes CHANGE YOUR VOTE! The SJSTOCKSHARK 12/07/17 10:28:31 AM
#3355   And from page 28: blairsoldman 12/06/17 11:01:59 PM
#3354   Running, I am not a securities expert. I SJSTOCKSHARK 12/06/17 10:11:00 PM
#3353   SJ, I know you are very cynical about Runninonempty 12/06/17 05:39:56 PM
#3352   Blair is correct. Just look at the chart SJSTOCKSHARK 12/06/17 05:23:35 PM
#3351   Not yet, it went under 20 cents too soon. iloveu2 12/06/17 03:24:05 PM
#3350   What does the proxy statement (sent with the blairsoldman 12/06/17 01:12:11 PM
#3349   The authorized shares get reversed on the split Runninonempty 12/06/17 12:36:09 PM
#3348   Sorry to those who are experts but I blairsoldman 12/06/17 11:44:25 AM
#3347   The market cap is now at less than SJSTOCKSHARK 12/06/17 11:32:02 AM
#3346   ilove, We broke $.20 are you buying? SJSTOCKSHARK 12/06/17 09:55:47 AM
#3345   Hal Mintz probably has a special seat in Richby30 12/05/17 12:46:31 PM
#3344   I am invested in another bio that just too simple 12/04/17 05:21:49 PM
#3343   Word, My fears when I read the registration SJSTOCKSHARK 12/04/17 04:53:30 PM
#3342   The timing of this stock dump and the wordlender 12/04/17 02:48:51 PM
#3341   Does a $.23 PPS mean a job well SJSTOCKSHARK 12/04/17 11:21:54 AM
#3340   Blair, thanks for your insightful response . I'm Johnbanks1 12/04/17 10:38:35 AM
#3339   I am not generally a "conspiricy theory" believer blairsoldman 12/03/17 09:49:56 PM
#3338   Bitcoin $11,800. I won’t post any more iloveu2 12/03/17 03:24:31 PM
#3337   Excuse my wording. Not the "only reason". I Johnbanks1 12/02/17 07:16:01 PM
#3336   Posting on a message board that is “followed” dmoffat 12/02/17 12:21:04 PM
#3333   The price drop is not a surprise, Since Gpheart2016 12/01/17 02:58:32 PM
#3332   Aren’t we all waiting for the price to Since2008 12/01/17 02:07:30 PM
#3331   Any comments on the sudden surge in volume Gpheart2016 12/01/17 01:55:13 PM
#3330   Good question! I'm not sure. wordlender 11/29/17 01:50:56 PM
#3329   Thanks Word. I went over the May SEC SJSTOCKSHARK 11/29/17 11:25:07 AM
#3328   They issued these new warrants back in May wordlender 11/29/17 07:30:13 AM
#3327   Bitcoin $10,500 iloveu2 11/29/17 12:12:44 AM
#3326   Word, I read that section. I may be SJSTOCKSHARK 11/28/17 11:01:30 PM
#3325   "This prospectus relates to the resale from time wordlender 11/28/17 08:09:55 PM
#3324   My new theory of collusion. SJSTOCKSHARK 11/28/17 11:54:43 AM
#3323   I agree SJS, in my opinion if they too simple 11/27/17 01:17:59 PM
#3322   SJ, 100% agree with everything you said! The Brettj 11/27/17 01:00:47 PM
#3321   If a $.22 pps is not a sufficient SJSTOCKSHARK 11/27/17 11:15:28 AM
#3320   $9,650 now, this thing is crazy! iloveu2 11/26/17 08:20:51 PM
PostSubject